DiagnoCure, Lab21 Ink UK Sales Pact | GenomeWeb

NEW YORK (GenomeWeb News) - DiagnoCure said today that Lab21 will sell its colorectal cancer staging test in the UK and Ireland.

Under the exclusive agreement, Lab21 will promote and sell the Previstage GCC Colorectal Cancer Staging Test in the two countries as part of its oncology testing services. DiagnoCure said that it will process the patient samples in its clinical lab in the US.

The company said that around 9,600 people in the UK could benefit from using the test for planning treatment staging each year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.